Related Experiment Video
Updated: May 22, 2026
09:02
Characterization of Intra-Cartilage Transport Properties of Cationic Peptide Carriers
Published on: August 10, 2020
Antiangiogenic and anticancer molecules in cartilage
Debabrata Patra1, Linda J Sandell
1Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Expert Reviews in Molecular Medicine
|May 8, 2012
Summary
Cartilage molecules like thrombospondin-1 and endostatin show antiangiogenic properties. While promising in preclinical cancer trials, their clinical success as anticancer agents is still under investigation.
Area of Science:
- Biochemistry
- Oncology
- Tissue Engineering
Background:
- Cartilage is a unique avascular tissue where lack of angiogenesis is key to its function.
- Its avascular nature inspires antiangiogenic cancer therapies.
- Cartilage's specialized extracellular matrix contains molecules with potential anti-cancer properties.
Purpose of the Study:
- To review antiangiogenic molecules derived from cartilage.
- To highlight promising anti-cancer agents.
- To evaluate the future of cartilage-derived antiangiogenic therapies.
Main Methods:
- Review of scientific literature on cartilage-derived antiangiogenic factors.
- Analysis of in vitro and in vivo preclinical data.
- Evaluation of human clinical trial outcomes.
Main Results:
- Several cartilage components, including thrombospondin-1, endostatin, and SPARC, exhibit antiangiogenic and antitumor properties.
- These molecules employ complex mechanisms not fully understood.
- While showing promise in preclinical studies, clinical success in cancer treatment remains limited.
Conclusions:
- Cartilage-derived molecules offer potential for antiangiogenic cancer therapy.
- Further research is needed to overcome challenges in clinical translation.
- Optimizing delivery and understanding mechanisms are crucial for future applications.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:27Growth of Cartilage and Bone Tissue
Chondrocytes form a temporary cartilaginous model by dividing and secreting a thick gel-like extracellular matrix. Once the chondrocytes undergo programmed cell death, osteoblasts enter the site of the cartilaginous model. The process of replacing the temporary cartilaginous model with bone in an ordered manner is called endochondral ossification. In endochondral ossification, not all of the cartilage is replaced by bone tissue. Some cartilage that performs a protective and supportive function...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...